Every Form 4 that Corvus Pharmaceu (CRVS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CRVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRVS filings page.
Corvus Pharmaceuticals director David Scott Moore reported buying shares and receiving stock options. He completed an open-market purchase of 21,700 shares of Common Stock at an average price of $11.5316 per share, and now holds 21,700 common shares directly.
He was also granted a stock option for 15,000 shares of Common Stock at an exercise price of $11.60 per share. The option vests in full on the earlier of the first anniversary of the grant date or the date of Corvus Pharmaceuticals’ 2027 Annual Meeting of stockholders, assuming continuous service as a director until that vesting date.
Corvus Pharmaceuticals director Ian T. Clark received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $11.60 per share and expire on June 11, 2036, representing compensation rather than an open-market purchase.
The underlying shares vest and become exercisable in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, assuming he continues serving as a director through that date. After this grant, Clark holds stock options for 15,000 shares from this award.
Corvus Pharmaceuticals director Linda Grais received a grant of stock options as equity compensation. The Form 4 shows an award of 15,000 options to buy Common Stock at an exercise price of $11.6000 per share, expiring on June 11, 2036.
The underlying 15,000 shares vest and become exercisable 100% on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of stockholders, assuming she continues to serve as a director through that vesting date.
Corvus Pharmaceuticals director Peter A. Thompson reported a grant of stock options covering 15,000 shares of Common Stock. The options have an exercise price of $11.6000 per share and expire on June 11, 2036. They vest in full on the earlier of the first anniversary of the grant date or the date of Corvus’ 2027 annual stockholders’ meeting, assuming continuous board service through that date. Under an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, any securities or economic benefits from these options are to be provided to OrbiMed Private Investments V, LP, and Thompson disclaims beneficial ownership except to any pecuniary interest.
Corvus Pharmaceuticals director Richard van den Broek received a new stock option grant. On the reported date, he was awarded options to buy 15,000 shares of Corvus common stock at an exercise price of $11.60 per share. All 15,000 options vest in a single tranche on the earlier of the first anniversary of the grant or the company’s 2027 annual stockholder meeting, assuming he continues serving as a director until that vesting date.
Corvus Pharmaceuticals, Inc. President and CEO Dr. Richard A. Miller reported additional open-market purchases of the company’s common stock. Through the Miller-Horning Family Trust, where he shares voting and investment power, the trust bought 1,932 shares at $12.01 per share and 5,000 shares at $12.05 per share on May 18, 2026, totaling 6,932 shares. After these transactions, he reports 1,136,707 shares held directly and 1,195,035 shares held indirectly through the trust.
Corvus Pharmaceuticals director Andrew C. Chan received a grant of stock options for 30,000 shares of common stock. The options have an exercise price of $16.02 per share and expire on April 23, 2036. All 30,000 options were reported as directly owned following the grant.
The footnote explains that these options vest in three equal annual installments. One-third of the shares subject to the option will vest on each annual anniversary starting April 23, 2026, as long as Chan continues his service relationship with Corvus on each vesting date.
Corvus Pharmaceuticals director and 10% owner Peter A. Thompson reported multiple option exercises linked to OrbiMed-affiliated entities. On 01/28/2026, stock options covering 210,000 shares of common stock were exercised at strike prices ranging from $0.965 to $15, resulting in 210,000 shares of common stock reported as directly owned.
An additional 8,609,091 shares of common stock are reported as indirectly owned through OrbiMed Private Investments V, LP and related OrbiMed entities. The filing states that Thompson, OrbiMed Advisors and OrbiMed Capital GP V LLC each disclaim beneficial ownership of these securities except to the extent of any pecuniary interest.
Corvus Pharmaceuticals, Inc. reported an insider equity award to its President, CEO and Director, Richard A. Miller. On 12/04/2025 he was granted a stock option to purchase 1,000,000 shares of Corvus common stock at an exercise price of $8.81 per share.
The option expires on 12/04/2035 and the underlying shares vest in equal monthly installments. Specifically, 1/36th of the shares vest each month starting on December 4, 2025, as long as he continues his service relationship with the company. Following this grant, he directly holds 1,000,000 derivative securities in the form of stock options.
Corvus Pharmaceuticals reported that its Chief Business Officer, Jeffrey Arcara, acquired a stock option covering 100,000 shares of common stock on December 4, 2025. The option has an exercise price of $8.81 per share and is held directly.
The underlying shares vest in equal monthly installments, with 1/36 of the shares vesting each month starting from December 4, 2025, as long as Arcara continues his service with the company. The option expires on December 4, 2035, and following this transaction he beneficially owned 100,000 stock options.
Corvus Pharmaceuticals, Inc. (CRVS) reported an insider equity transaction by Director David Scott Moore on 10/02/2025. The filing discloses an award of 30,000 stock options with an exercise price of $7.04. The options vest in three equal annual installments (one-third each year) beginning on 10/02/2025 and expire on 10/02/2035 subject to the reporting person’s continued service. The Form 4 was signed on 10/06/2025 by an attorney-in-fact on behalf of the reporting person.